ITOS (iTeos Therapeutics) חוב לטווח קצר להון

The market trend for iTeos Therapeutics (ITOS) shares demonstrates the 0.00 indicator. The company's revenues are based on the development of cancer therapies and payments from its strategic partner GSK. High competition in the patent landscape creates risks of losing market position. Meanwhile, the business relies on external research centers, controlling test quality through strict regulatory oversight by management.

This metric measures the company's reliance on obligations with maturities of up to one year relative to its equity, allowing investors to differentiate a strategic liquidity reserve from stagnation via the dynamics of the short-term debt-to-equity structure, which is critical for iTeos Therapeutics (ITOS), whose viability during clinical trials without commercial revenue relies entirely on the remnants of past partnership payments.